فهرست و منابع تحقیق مقاله استفاده از اشکال دارویی پیوسته رهش جهت جلب رضایت بیمار
فهرست:
ندارد
منبع:
REFERENCES
1- H.S.Hall and R.E pondell,the wurster process, in controlled release Technologies: Methods, theory and Application s, Vol II (A.F.Ky donieul, ed.), CRC press, Boca raton, florida, PP.137 (1986)
2- Issac Ghebre- Sellassie, Pharmaceutical, pelletiztion technology, Marcel Dekker, Inc. New York Basel, 1989: 224
3- دکتر مرتضی رفیعی تهران، مبادی فرمولاسیون اشکال دارویی پیوسته رهش خوراکی صفحات مختلف.(3 و 17 و 53 و 63 و 137 و 185 و 273 و 281 و 313).
4- MENDELL APENWEST COMPANY 1996.
5- The United State pharmacopeia. Twenty- third revision. United States pharmacopeial convention Inc., Rocville, MD, 1995: 1580, <724>; 1577, <701>.
6- Ghebre- sellasie I.In I. Ghebre-sellasie (ed.), Multiparticulate oral delivery, marcel Dekker, New York, 1994.
7- Rohm pharma polymers aplication of EUDRAGIT X4.1.9.2 Diclofenac, do c/1/Fe.02/page 1,2,3.
8- “practical course in Lacquer coation”, Lehman et al.
9- Http: //WWW. Rohma pharma. Com/product %20 Demonstration/ EUDRAGIT- Files/ slide 0044, htm 8/20/2002.
10- The MERCK INDEX, THIRTEENTH EDITION, 2001, pp.345, 1359,1362,1613.
11- فرمولاسیون و تکنولوژی تولید فرآورده‌های آرایشی و بهداشتی و حفاظت میکروبی آنها ترجمه و تألیف مهندس سید اسداله عمرانی، صفحه 491، 521.
12- Professor JEAN- MAURICE VERGNAUD, Drug- Carbopol. Sheet, COTROLLED DRUG RELEASE OF ORAL DOSAGE FORMS, First published in 1993 by Ellis Horwood limited pp.225 (1993).
13- Gennaro, A.R. “Remington’s pharmaceutical sciences” 18 Th ed. Mack publishing company, Easton, Ponsylvania, pp. 1504-1508, 1126, 36,37 (1996).
14- Mechkovski, A. “who Guidelines on stability testion of pharmaceutical products (1991) wt/o Geneva, Switzerland (1991).
15- Goodman and Gilman’s the pharmacological basis of theraputics 669, 1991.
16- Todd, peter A., Diclofenac sodium, Drugs, Vol: 35, 244-285, 1988.
17- Drug Facts and comparision, 1991.
18- Ullman’s Encyclopedia of Industerial chemistry Vol: 9,509-529.
19- Maysinger, D.prepartion and invitro effect of micro encapsulation cholinotoxin int.y. Pharm (63) 149- 153, 1990.
20- Torres, D.g Garcia- Encina, G.etal. ‘Formulation and invitro evaluation of HPMCP- micro encapsulated drug-resion complexes for SR of diclofencac’ , int. J. pharm, 121: 239- 243, 1995.
21- Liu, C.H., Kao, Yott, et al. “in vitro and invivo studies of the diclofenac sodiom controlled release matrix tablests”, J. Pharm. Phama col. 47: 260- 364, 1995.
22- Therapeutic drugs. 2nd. Ed. Churchill Livingston, USA, Vol. 1,pp, D96- D100, 1991.
23- Physical pharmacy Martin, Micromeritics, part 18, pp 493.
24- Hosny EA, EI- Mahrouk GM, Gouda MW. Formulation and invitro and invivo availability of diclofenac sodium enteric- coated beads.
Drug. Dev. Ind. Pharm. 1998; 24: 661-666.
25- Claudio Nastruzzi, Rita cortesi, Elisabetta Esposito, Alberto Genovesi, Alessandro spadoni, carlo ve cchi, Enea Menegatti. Influence of formulation process parameters on pellet production by powder layering Technique, AAPS. Pharm. Sci. Tech, 2000 ; 1(2) article 9 chttp://www. Pharm Sci.tech. Com/)
26- C.T. Rhodes and S.C. porter. Coations for controlled – Release Drug delivery systems, Drug. Dev. Ind. Pharm, 1998; 24 (12): 1139-1154.
27- United States patent, patent number 4,948, 581.
28- A. Bodea and S.E. Leucuta. Optimization of propranolol Hydrochloride sustained- Release pellets using Box- Behnken Design and Desirability function, Drug. Dev. Ind. Pharm. 1998; 24 (2): 145-155.
29- Shrutiu. Bhat and J.K, Lalla, Alook AT PROCESS COSTING AND COST–EFFECTIVENESS OF A PHARMACEUTICAL FORMULATION
. India DRUGS, 1995; 32(1): 551-559.
30- Bhat S.U. and Lalla J.K. “2! Factorial approcach to optimiztion of coating for pellet preparation: coating pan VS dish pelletiser”; Indian grugs; 1992; 29: 527.
31- F. Fabiani and C.Vechio, fluidized- bed rotogranulation to prepare extended drug release multiple unit dosage. Forms, acta technol. Legis Med., 1993; 1,57.
32- C.Vecchio, F. Fabiani, M.E. Sangalli, L. Zema and A. Gazzaniga. Rotary tangential spray technique for Aqueous film coating of Indobufen pellets. Drug Dev. Ind. Pharm. 1998; 24 (3): 262- 274.
33- Rohm Pharma polymers, Rohm GMBH and co. KG, Dormstadt, Germany,. Sustained-Release formulations for oral dosage forms. (http://www. Rohm pharma. Com/ eudragit); 2001.
34- http:/www. Rohm pharma/ HTML/ trouble %20 shooting. htm. 8/20/2002.
35- 2000 The United States pharmacopeial convention, Inc. Rockville, MD. 2000; USP 24-NF 19 Through supplement two, sugar spheres, syrup, … page No. 547.
36- MORTEZA RAFIEE- TEHRANI. AND N. SADEGH- SHOBEIRI. Drug. Dev. Ind. Pharm. 1995; 21 (10): 1193- 1202. EFFECT OF VARIOUS POLYMERS IN FORMULATION OF CONTROLLED RELEASE (CR) IBUPROFEN PELLETS BY FLUID BED TECHNIQUE.
37- MORTEZA RAFIEE- TEHRANI, ZAHRA JAFARI- AZAR formulation of theophylline controlled- Release Tablets : invitro/ invivo and stability studies. Acta. Pharma. 48 , 1998; 155-166.